Hospital-acquired infection Diagnostics Market Expected to Reach $4,311 Million by 2023
The hospital-acquired infections diagnostics market is projected to grow steadily owing to the adoption of the data analytics to improve healthcare facilities. In addition, the market in developing economies is anticipated to grow rapidly due to the increase in occurrence of hospital-acquired infections due to poor sanitation conditions.
Sriram Radhakrishnan
Team Lead, Healthcare at AMR.
According to a new report published by Allied Market Research, titled, Hospital-acquired infection diagnostics Market by Product, Test Type, Application, Infection Type and End User: Global Opportunity Analysis and Industry Forecast, 2017-2023," the global hospital-acquired infection diagnostics market was valued at $2,571 million in 2016, and is projected to reach $4,311 million by 2023, growing at a CAGR of 7.5% from 2017 to 2023. The urinary tract infections (UTI) segment accounted for maximum share of the total market in 2016.
Access Full Summary at: https://www.alliedmarketresearch.com/hospital-acquired-infection-diagnostics-market
Hospital-acquired infection are contaminations caused by bacteria, viral, and fungal pathogens. These infections are usually acquired in clinical and hospital settings mainly due to an infected patient, outside environment, or from the staff of that facility.
Rise in prevalence of infections from hospitals and clinical settings drive the market. However, the lack of awareness regarding hospital-acquired infection diagnostics impedes the market growth. Moreover, the technological advancements in healthcare sector for the innovation of novel and sophisticated products is projected to create lucrative opportunities for key market players.
Drug resistance testing segment is anticipated to maintain its dominance during the forecast period, accounting for major share of the global hospital-acquired infections diagnostics market. This is due to the benefits drug resistance testing offers such as they are cost-effective when the prevalence of drug resistance in chronically infected patients is low.
Key Findings of the Hospital-acquired Infection Diagnostics Market:
- The U.S. was the major shareholder in the North America hospital-acquired infection diagnostics market, and accounted for the highest share in 2016.
- Disease testing is expected to grow at the highest CAGR during 2017-2023.
- Japan occupied about two-ninths share of the total Asia-Pacific hospital-acquired infections diagnostics market in 2016.whereas, South Korea is expected to grow rapidly registering a CAGR of 8.3% during the forecast period.
- The immunoassay segment dominated the market in 2016, growing at a CAGR of 5.6% from 2017 to 2023.
- Molecular diagnostics accounted for about one fourth share of the total market share in 2016 and is expected to grow with a high CAGR of 12.8% during the forecast period.
In 2016, Asia-Pacific and LAMEA collectively accounted for about one fifth share of the global hospital-acquired infection diagnostics market and is expected to continue this trend throughout the forecast period. The key factors driving the market growth include the demand for hospital-acquired infection diagnostics from middle and low-income countries owing to the massive population and increase in prevalence of diseases.
The report provides a comprehensive analysis of the key players operating in the global hospital-acquired infection diagnostics market such as Abbott Laboratories, AdvanDX, Alere Inc., AstraZeneca plc, Bayer Schering Pharma LLC, Becton Dickinson and Company, Cepheid Inc., Roche AG, Daiichi Sankyo, and Hologic, Inc.
The other players in the value chain of the global hospital-acquired infection diagnostics market include GlaxoSmithKline plc, Johnson & Johnson, Merck & Co., Meridien, Pfizer, and Seegene.
Talk to David (Europe)
Talk to Sona Padman (Americas)
5933 NE Win Sivers Drive #205,
Portland, OR 97220 United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91 2066346060
Fax: +1(855) 550-5975
Ram D
Communications Officer
Allied Market Research
Contact Toll Free: +1-800-792-5285
Drop us an email at
media@alliedmarketresearch.com
Hospital-Acquired Infection Diagnostics Market by Product (Instrument & Reagents and Consumables), Test Type (Molecular Diagnostics, Urinalysis, and Immunoassay), Application (Disease Testing and Drug-Resistance Testing), Infection Type (Hospital Acquired Pneumonia, Bloodstream Infections, Surgical Site Infections, Gastrointestinal Infections, Urinary Tract Infections (UTI), and Others), and End User (Hospital, Clinics, Ambulatory Surgery Centers (ASC) and Others) - Global Opportunity Analysis and Industry Forecast, 2017-2023
Avenue: Entire Library membership of Allied Market Research Reports at your disposal
- Avenue is an innovative subscription-based online report database.
- Avail an online access to the entire library of syndicated reports on more than 2,000 niche industries and company profiles on more than 12,000 firms across 11 domains.
- A cost-effective model tailored for entrepreneurs, investors, and students & researchers at universities.
- Request customizations, suggest new reports, and avail analyst support as per your requirements.
- Get an access to the library of reports at any time from any device and anywhere.
Why Allied Market Research?
Infallible Methodology
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
Analyst Support
For complete satisfaction
Customization
On-demand customization of scope of the report to exactly meet your needs
Targeted Market View
Targeted market view to provide pertinent information and save time of readers
Featured Readings
Get Fresh content delivered
Get insights on topics that matter to your business. Stay updated on the area that interests you.
Buy Full Version
"Hospital-acquired infection Diagnostics Market"
Purchase Enquiry